172 related articles for article (PubMed ID: 21558622)
1. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
Tran L; Vogel WV; Sinaasappel M; Muller S; Baars JW; van Rijswijk M; Dinant HJ; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):7-14. PubMed ID: 21558619
[TBL] [Abstract][Full Text] [Related]
3. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Tran L; Baars JW; Aarden L; Beijnen JH; Huitema AD
Hum Antibodies; 2010; 19(1):7-13. PubMed ID: 20555126
[TBL] [Abstract][Full Text] [Related]
6. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
7. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
8. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
Boucek JA; Turner JH
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
[TBL] [Abstract][Full Text] [Related]
9. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
10. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
[TBL] [Abstract][Full Text] [Related]
11. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
12. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Leonard JP
Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054
[No Abstract] [Full Text] [Related]
13. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy in follicular lymphoma.
Illidge T; Morschhauser F
Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
17. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
18. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF
Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
